Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse.
Patients with resistant or recurrent acute lymphoblastic leukemia were treated with vindesine 3 mg/m2/IV weekly X 4, daunomycin 25 mg/m2/IV weekly X 4, and prednisone 40 mg/m2/PO daily X 28. Seventeen (44%) of 38 evaluable patients achieved complete remission. Fifty-one percent of 31 patients in first relapse achieved complete remission, while only one of five in second or third relapse and neither of two resistant to first induction achieved complete remission. The major toxicity was hematologic. The median duration of complete remission was only 6 weeks and median survival from start of the study, 3 months, with 22% patients remaining alive at 10 months. We conclude that the vindesine, prednisone, and daunomycin combination is no more effective than vincristine, prednisone, and daunomycin in achieving remission of relapsed acute lymphoblastic leukemia patients, and is more toxic than the latter regimen.
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects; D011379:Prognosis; D012008:Recurrence; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014751:Vindesine
D000970:Antineoplastic Agents; D014747:Vinblastine; D014751:Vindesine; D011241:Prednisone; D003630:Daunorubicin